Last updated: July 2026
The Ozempic lawsuit is active federal litigation claiming Novo Nordisk failed to warn patients that its GLP-1 drugs can cause gastroparesis, bowel obstruction, and sudden vision loss. Nearly 3,900 cases are pending in MDL 3094 as of July 2026. No settlements have been reached, and the first trials are not expected before 2027.
If you took Ozempic, Wegovy, Mounjaro, or a similar medication and suffered a serious injury, this guide explains where the litigation stands today, who qualifies to file, and what compensation could look like once cases resolve.
What Is the Ozempic Lawsuit About?
Ozempic belongs to a class of drugs called GLP-1 receptor agonists. Novo Nordisk makes Ozempic, Wegovy, and Rybelsus. Eli Lilly makes Mounjaro, Zepbound, and Trulicity. These medications slow how quickly the stomach empties, which helps control blood sugar and appetite.
Plaintiffs say that same mechanism can go too far. They allege the manufacturers knew about the risk of severe, sometimes long lasting stomach and bowel injuries and failed to warn patients and doctors. The FDA added ileus, a form of bowel obstruction, to the Ozempic label in September 2023 after reviewing adverse event reports.
These are failure to warn claims. The court has already dismissed design defect theories, but the core warning claims survived and are moving forward.
Injuries at the Center of the Claims
| Injury | What It Means | Where It Stands |
|---|---|---|
| Gastroparesis (stomach paralysis) | The stomach empties too slowly or stops emptying, causing vomiting, pain, and malnutrition | Core injury in MDL 3094; claims must be backed by a gastric emptying study |
| Ileus and intestinal obstruction | The bowel stops moving or becomes blocked, sometimes requiring surgery | Included in MDL 3094; supported by the 2023 FDA label change |
| NAION (sudden vision loss) | Optic nerve damage that can cause permanent partial or total blindness | Centralized in a separate proceeding, MDL 3163, in December 2025 [VERIFY] |
| Gallbladder disease and pancreatitis | Inflammation or gallstone complications, sometimes requiring gallbladder removal | Alleged in some individual complaints alongside the main injuries |
Who Qualifies to File a Claim?
Law firms reviewing GLP-1 cases generally look for the same core facts. You do not need to have taken Ozempic specifically. Claims involving Wegovy, Rybelsus, Saxenda, Victoza, Mounjaro, Zepbound, and Trulicity are part of the same federal litigation.
Most firms want to see:
- Documented use of a GLP-1 medication, through prescription records or pharmacy records
- A diagnosed injury such as gastroparesis, ileus, intestinal obstruction, or NAION
- Medical records connecting the injury to the period during or shortly after use
- For gastroparesis, a properly performed gastric emptying study confirming the diagnosis
The gastric emptying study requirement matters. In 2025, Judge Karen Spencer Marston ruled that gastroparesis plaintiffs must show their diagnosis rests on a properly performed gastric emptying study. Cases built on symptoms alone, without objective test results, face dismissal.
Where Does the Litigation Stand in July 2026?
All federal cases are consolidated in MDL 3094, formally titled In re: Glucagon-Like Peptide-1 Receptor Agonists Products Liability Litigation, before Judge Marston in the Eastern District of Pennsylvania. The panel centralized the cases in February 2024, when only a few dozen suits existed. As of July 1, 2026, roughly 3,848 cases were pending, and filings continue to climb.
The next major event is a Rule 702 expert hearing scheduled for September 10-18, 2026. At that hearing, the court will decide whether the scientific experts on both sides can testify about general causation, warning adequacy, and preemption. This is the single biggest inflection point in the litigation. If plaintiffs’ experts are excluded, thousands of cases could collapse. If they are admitted, settlement pressure on Novo Nordisk and Eli Lilly rises sharply.
No bellwether trials have been scheduled. Based on the current calendar, the first trials are unlikely before 2027.
Key Milestones So Far
| Date | What Happened |
|---|---|
| September 2023 | FDA added ileus to the Ozempic label |
| February 2024 | Federal panel centralized GLP-1 cases into MDL 3094 |
| 2025 | Court required gastric emptying studies for gastroparesis claims and dismissed design defect theories |
| December 2025 | Separate MDL 3163 created for NAION vision loss claims [VERIFY] |
| July 2026 | Roughly 3,848 cases pending as of July 1 |
| September 2026 | Rule 702 expert hearings set for September 10-18 |
How Much Compensation Could an Ozempic Lawsuit Pay?
Nobody has been paid yet. There are no settlements, no jury verdicts, and no official claim forms. Any website promising a specific payout today is guessing, and you should treat exact promises with caution.
That said, attorneys handling these cases have published working estimates based on outcomes in comparable drug litigation. Severe gastroparesis cases involving hospitalization, feeding tubes, or permanent dysfunction are often projected in the range of $200,000-$500,000. Moderate cases with documented treatment but good recovery are commonly estimated at $50,000-$150,000. NAION vision loss cases are projected higher, potentially $500,000 or more, because blindness is permanent. [VERIFY] These figures are unofficial projections, not guarantees.
If settlements happen, individual amounts will depend on:
- How severe and how permanent the injury is
- Whether you needed surgery, a feeding tube, or repeated hospital stays
- Lost income and ongoing medical costs
- The strength of your medical records and diagnostic testing
- How clearly your records rule out other causes
What Should You Do if You Were Injured?
A few practical steps protect both your health and any future claim.
- Get medical care first. Do not stop a prescribed medication without talking to your doctor.
- Ask about a gastric emptying study if you have ongoing vomiting, bloating, or early fullness. Objective testing is now essential to these claims.
- Save your records. Keep pharmacy printouts, prescription history, hospital records, and imaging results.
- Write down your timeline. Note when you started the drug, when symptoms began, and every treatment since.
- Talk to a lawyer before deadlines pass. Product liability firms handle these cases on contingency, so consultations are free.
Deadlines are real. Each state has its own statute of limitations, often two to three years from the injury or from the date you discovered the drug may have caused it. Waiting too long can end a valid claim before it starts.
The Ozempic lawsuit is moving, but slowly and carefully, which is normal for mass tort litigation of this size. The September 2026 expert hearings will shape whether these claims head toward trials and settlement talks in 2027. If you suffered gastroparesis, a bowel obstruction, or vision loss after taking a GLP-1 drug, the practical move is simple: preserve your records now and get a case review before your state deadline runs out.
Frequently Asked Questions
Has anyone received an Ozempic settlement yet?
No. As of July 2026, there are no settlements, jury verdicts, or court approved payouts in the federal GLP-1 litigation. The cases remain in the pretrial phase, with a major expert evidence hearing set for September 2026. Any dollar figures you see online are attorney projections, not actual results.
What could my case be worth?
There is no official number yet. Attorney projections based on similar drug litigation suggest severe gastroparesis cases could resolve in the $200,000-$500,000 range, moderate cases at $50,000-$150,000, and permanent vision loss cases higher. Your actual result would depend on injury severity, medical proof, and how the litigation unfolds. Treat every estimate as unofficial.
Do Wegovy, Mounjaro, or Zepbound users qualify?
Yes. MDL 3094 covers GLP-1 drugs from both Novo Nordisk (Ozempic, Wegovy, Rybelsus, Saxenda, Victoza) and Eli Lilly (Mounjaro, Zepbound, Trulicity). The qualifying factor is a documented serious injury such as gastroparesis or bowel obstruction, not which brand you took. Vision loss claims proceed in a related federal docket.
Is it too late to file a claim in 2026?
For most people, no. New cases are still being filed and the litigation is years from finished. But each state sets its own statute of limitations, often two to three years from injury or discovery. The safest approach is to have a lawyer confirm your specific deadline as soon as possible.
How much does it cost to hire a lawyer?
Nothing upfront. Firms handling GLP-1 injury cases work on contingency, meaning they only get paid if you recover money, typically taking a percentage of the result. Initial case reviews are free. Be wary of anyone asking for payment before taking your case, as that is not how legitimate mass tort firms operate.
This article is general information, not legal or medical advice. Laws, deadlines, and case status change. Talk to a licensed attorney about your specific situation, and talk to your doctor before making any change to your medication.